The direct answer is that none of the peptides typically formulated into a GLOW blend, GHK-Cu (copper tripeptide-1), BPC-157, and TB-500 (a synthetic fragment related to thymosin beta-4), is an FDA-approved drug, and the three do not occupy a single regulatory status. US law recognizes no category called peptides; the Federal Food, Drug, and Cosmetic Act sorts a product by what it is intended to do and how it is presented, so one molecule can land in different lanes depending on the claim and the route. Injected BPC-157 and TB-500 sold to affect the structure or function of the body meet the statutory drug definition and, lacking any approved application, stand as unapproved new drugs, while topical GHK-Cu occupies a long-established cosmetic lane that says nothing about the legality of an injectable version.
| Peptide | What it is | Current US status |
|---|---|---|
| GHK-Cu (copper tripeptide-1) | Copper tripeptide, decades of topical cosmetic use | Accepted cosmetic ingredient topically; injectable use falls under the drug framework |
| BPC-157 | Synthetic pentadecapeptide, no approved application | Unapproved new drug when sold for human use |
| TB-500 | Synthetic fragment of thymosin beta-4 | Unapproved new drug when sold for human use |
None of GHK-Cu, BPC-157, or TB-500 is an FDA-approved drug, and because US law has no peptide category, an injectable GLOW preparation making structure-or-function claims is treated as an unapproved new drug.
The controlling fact is an absence: American law has no peptide category, so the Federal Food, Drug, and Cosmetic Act sorts each article by intended use rather than molecular structure. A drug under section 201(g) is anything intended to treat disease or to affect the structure or function of the body; a cosmetic under section 201(i) is anything applied to the body to cleanse or beautify. The definitions overlap by design, and blending three components does not create a fourth status, because a finished combination product is judged as a whole and takes the most stringent classification its intended use triggers.
The Federal Food, Drug, and Cosmetic Act classifies each article by intended use under sections 201(g) and 201(i), and a blended injectable product takes the most stringent classification its use triggers, which is the drug framework.
No. As of this writing, none of the three carries an approved New Drug Application or Biologics License Application for any indication, and FDA's approved-drug listings return nothing for BPC-157, TB-500, thymosin beta-4, or copper tripeptide-1 as a drug active ingredient. The distinction that peptide marketing most often blurs is between approval and investigation: thymosin beta-4 has a real investigational history under an IND, studied in human trials for dry eye and wound repair, but an IND is permission to study a drug under protocol, not permission to sell it.
| Dimension | FDA approval (NDA/BLA) | Investigational (IND) |
|---|---|---|
| What it authorizes | Lawful manufacture, labeling, and promotion for a use | Study under protocol only, no sale |
| Evidence required | Substantial evidence from adequate, well-controlled trials | A protocol, IRB oversight, informed consent |
| Status of these peptides | None hold it | Thymosin beta-4 reached it; none is approved |
None of BPC-157, TB-500, thymosin beta-4, or copper tripeptide-1 holds an approved New Drug Application or Biologics License Application for any indication in the United States, and an investigational IND history is not approval and confers no right to sell.
Compounding is the pathway most often cited to explain how an unapproved peptide reaches a patient lawfully, and it is also the one that has narrowed most sharply. Section 503A exempts a pharmacist or physician compounding for an identified patient from the approval requirement, but only if the bulk drug substance has a USP or NF monograph, is a component of an FDA-approved drug, or appears on the 503A bulks list. These peptides satisfy none of the three, so a recent shift in their listing status changes less than it appears to.
A bulk drug substance qualifies for 503A compounding only with a USP or NF monograph, status as a component of an FDA-approved drug, or a place on the 503A bulks list, and BPC-157 and the TB-500 fragment meet none of these even after moving from Category 2 to the nominated-but-withdrawn list.
No, and two independent barriers each close the lane on their own. The first is the closed statutory definition of a dietary ingredient in section 201(ff)(1); a synthetic fifteen-amino-acid peptide is not an amino acid in the singular sense the statute means, not a botanical, and has no history in the food supply, so it lands nowhere on the list. The second is the drug-preclusion clause at 201(ff)(3)(B), which excludes any article authorized for investigation as a new drug once substantial public clinical investigations began, a live problem given thymosin beta-4's trial history.
A synthetic peptide such as BPC-157 fails the closed dietary-ingredient definition in section 201(ff)(1) and is separately blocked by the drug-preclusion clause in 201(ff)(3)(B), so it cannot be lawfully marketed in or as a dietary supplement.
Route and claim together, not the molecule alone, are what separate GHK-Cu from its blendmates. A cosmetic is an article applied to the body to beautify or alter appearance, and cosmetics carry no premarket approval requirement, which is the lane copper tripeptide-1 has occupied for decades in serums sold on appearance claims. Change either variable, the claim or the route, and the classification changes with it.
Topical copper tripeptide-1 sold on appearance claims is a cosmetic requiring no premarket approval, but a drug-style claim or an injectable route moves the same molecule into the drug framework as an unapproved new drug.
A research use only or not for human consumption sticker is a marketing convention, not a legal status conferred by anyone. The phrase has a legitimate origin in the laboratory-reagent trade, but peptide vendors have borrowed it for products dosed in milligrams, supplied with bacteriostatic water, priced per cycle, and discussed publicly in terms of human results. FDA determines intended use from the totality of the evidence, looking past the label to website copy, dosing charts, testimonials, and the knowledge that buyers are individuals rather than laboratories.
| Dimension | Research use only label | Investigational new drug (IND) |
|---|---|---|
| What it is | A seller's marketing convention | An FDA authorization to study in humans |
| Oversight | None: no protocol, IRB, or consent | Protocol, IRB, informed consent, adverse-event reporting |
| Legal effect | Does not shield intended use from FDA review | Permits investigation, not sale |
Research use only labeling is a marketing convention with no legal force, because FDA determines intended use from the totality of a seller's evidence, and such disclaimers have repeatedly failed to shield vendors marketing peptides for human use.
The exposures land very differently on the two ends of the transaction, a distinction often missed. The Act's prohibitions target commerce, introducing an unapproved new drug into interstate commerce, misbranding, adulteration, and they do not make a consumer's personal possession or self-administration a federal offense; these peptides are not controlled substances. The prescriber sits far more exposed, because a state medical board reviewing a complaint will ask why a practitioner chose a substance FDA has flagged as raising significant safety risks over an approved alternative.
Federal law does not criminalize a consumer's personal possession of these non-controlled peptides, but a prescriber who sources and injects them carries far greater exposure, including state medical-board review, heightened malpractice risk, and denied insurance coverage.
Enforcement has been real but uneven, and reading it accurately means holding two facts at once: the legal position is unambiguous, and the policing of it is intermittent. FDA's toolkit runs as a ladder, and most of what happens in the peptide space happens on its bottom rung, with warning letters that read remarkably alike from one firm to the next. The compounding side moved differently, FDA changing the terrain by categorizing the substances rather than pursuing pharmacies one by one, and a number of pharmacies exited peptide compounding once continuing meant operating outside stated enforcement discretion.
FDA enforcement escalates from public warning letters through import alerts, seizures, and injunctions to criminal referral, but most peptide-space action stays on the warning-letter rung, leaving a wide gap between the law and its enforcement that functions as a backlog, not a safe harbor.
For anyone in a tested sport, this is the most immediately consequential framework of all, and it is stricter than FDA's. Both BPC-157 and TB-500 are prohibited under the World Anti-Doping Code at all times, in and out of competition, so an off-season cycle is a violation just as a race-day dose would be. Even setting aside the specific entries, category S0 catches any substance not approved by any government health authority for human therapeutic use, meaning an unapproved peptide is banned by virtue of being unapproved.
BPC-157 and TB-500 are prohibited for tested athletes at all times under the World Anti-Doping Code, both by specific listing and by the S0 catch-all covering any substance not approved for human therapeutic use, under a strict-liability standard.
Forecasting is not the point; understanding which levers could move is, and three exist. The 503A list is explicitly provisional and has already shifted once, with both peptides now on the agenda of a Pharmacy Compounding Advisory Committee meeting weighing them for the bulks list, evaluated for ulcerative colitis (BPC-157) and wound healing (TB-500). Approval by a sponsor would change everything at once, though unpatentable peptides already selling on the gray market make a poor investment case, and enforcement posture can tighten or loosen quickly without any change in the underlying law.
The status here can shift through three levers, the provisional 503A list now under Pharmacy Compounding Advisory Committee review, a sponsor pursuing full approval, and enforcement posture, so any specific claim should be checked against FDA's current pages and the current WADA list rather than treated as fixed.
Educational use only. This article describes what the published scientific and clinical literature reports about GHK-Cu, BPC-157, and TB-500. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
